XML 56 R38.htm IDEA: XBRL DOCUMENT v3.25.1

Restructuring, Impairment, and Related Charges, Net (Tables)

12 Months Ended

Mar. 31, 2025

Restructuring and Related Activities [Abstract]

Summary of Details for Charges Recorded

Restructuring, impairment, and related charges, net for the year ended March 31, 2025 consisted of the following:

			Year Ended March 31, 2025
(In millions)			U.S. Pharmaceutical (1)						Prescription Technology Solutions						Medical-Surgical Solutions (2)						International						Corporate						Total
Severance and employee-related costs, net			$	(2)					$	—					$	137					$	—					$	3					$	138
Exit and other-related costs (3)			3						3						53						—						49						108
Asset impairments and accelerated depreciation			58						9						14						1						16						98
Total			$	59					$	12					$	204					$	1					$	68					$	344

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s U.S. Pharmaceutical segment, including an inventory impairment of $58 million within "Cost of sales" in the Consolidated Statement of Operations.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Fiscal 2024

Restructuring, impairment, and related charges, net for the year ended March 31, 2024 consisted of the following:

			Year Ended March 31, 2024
(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions (1)						Medical-Surgical Solutions						International						Corporate (1)						Total
Severance and employee-related costs, net			$	10					$	—					$	(1)					$	2					$	(1)					$	10
Exit and other-related costs (2)			3						11						12						9						27						62
Asset impairments and accelerated depreciation			4						—						—						10						29						43
Total			$	17					$	11					$	11					$	21					$	55					$	115

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Fiscal 2023

Restructuring, impairment, and related charges, net for the year ended March 31, 2023 consisted of the following:

			Year Ended March 31, 2023
(In millions)			U.S. Pharmaceutical (1)						Prescription Technology Solutions (1)						Medical-Surgical Solutions						International						Corporate (1)						Total
Severance and employee-related costs, net			$	6					$	23					$	2					$	4					$	—					$	35
Exit and other-related costs (2)			7						7						3						21						64						102
Asset impairments and accelerated depreciation			25						13						5						10						19						72
Total			$	38					$	43					$	10					$	35					$	83					$	209

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Corporate includes costs for business transformation and optimization efforts related to the Company’s technology organization. The International segment includes costs related to the Company’s European divestitures.

Schedule of Restructuring Reserve by Type of Cost

The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2025 and 2024:

(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions						Medical-Surgical Solutions						International						Corporate						Total
Balance, March 31, 2023 (1)			$	15					$	26					$	3					$	13					$	35					$	92
Restructuring, impairment, and related charges, net			17						11						11						21						55						115
Non-cash charges			(4)						—						—						(10)						(29)						(43)
Cash payments			(15)						(32)						(13)						(5)						(40)						(105)
Other (2)			5						—						—						(9)						—						(4)
Balance, March 31, 2024 (3)			18						5						1						10						21						55
Restructuring, impairment, and related charges, net			59						12						204						1						68						344
Non-cash charges			(58)						(9)						(14)						(1)						(16)						(98)
Cash payments			(8)						(4)						(99)						(2)						(51)						(164)
Other (2)			(1)						(3)						(2)						(7)						2						(11)
Balance, March 31, 2025 (4)			$	10					$	1					$	90					$	1					$	24					$	126

(1)    As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.

(2)    Other primarily includes cumulative translation adjustments as well as adjustments to Canadian retail disposal group reserves within International in fiscal 2025, and transfers to certain other liabilities for the remainder segments.

(3)    As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in “Other accrued liabilities” and $31 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.

(4)    As of March 31, 2025, the total reserve balance was $126 million, of which $103 million was recorded in “Other accrued liabilities” and $23 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.

X

- References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details

Name:	us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4.b.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details

Name:	us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration